《CMI,6月18日,The ORF3a protein of SARS-CoV-2 induces apoptosis in cells》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-06-20
  • The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

    Yujie Ren, Ting Shu, Di Wu, Jingfang Mu, Chong Wang, Muhan Huang, Yang Han, Xue-Yi Zhang, Wei Zhou, Yang Qiu & Xi Zhou

    Cellular & Molecular Immunology (2020)Cite this article

    Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the ongoing pandemic of Coronavirus Disease 2019. SARS-CoV-2 belongs to the genus Betacoronavirus of the Coronaviridae family, which includes SARS-CoV and Middle East respiratory syndrome coronavirus.1,2 Coronavirus-encoded accessory proteins play critical roles in virus–host interactions and the modulation of host immune responses, thereby contributing to coronaviral pathogenicity via different strategies.3 However, the functions of SARS-CoV-2-encoded accessory proteins are not well understood. Apoptosis is a predominant type of programmed cell death, and has been recognized as an important host antiviral defense mechanism that controls viral infection and regulates the inflammatory response.4,5 Previous studies have reported that the SARS-CoV-encoded accessory protein ORF3a can induce apoptosis in cells,6,7 leading to the question of whether SARS-CoV-2 ORF3a also has pro-apoptotic activity. Here, we investigated the potential apoptosis-inducing activity of SARS-CoV-2 ORF3a in different cell lines and compared the pro-apoptotic activities of SARS-CoV-2 ORF3a with those of SARS-CoV ORF3a using the same system.

  • 原文来源:https://www.nature.com/articles/s41423-020-0485-9
相关报告
  • 《6月18日_武汉病毒所等团队研究证实SARS-CoV-2的ORF3a蛋白诱导细胞凋亡》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-20
    • 1.时间:2020年6月18日 2.机构或团队:中国科学院武汉病毒研究所-广州市妇女儿童医疗中心精准转化医学研究中心、中国科学院武汉病毒研究所、武汉金银滩医院、武汉大学、中国科学院大学 3.事件概要: Nature子刊Cellular & Molecular Immunology 于6月18日发表了中国科学院武汉病毒研究所-广州市妇女儿童医疗中心共建的精准转化医学研究中心等研究机构的通讯文章“The ORF3a protein of SARS-CoV-2 induces apoptosis in cells”。文章研究了SARS-CoV-2 ORF3a在不同细胞系中的潜在凋亡诱导活性,并使用同一系统比较了SARS-CoV-2 ORF3a和SARS-CoV ORF3a的促凋亡活性。 研究人员利用使用膜联蛋白V-荧光素5-异硫氰酸酯(FITC)/碘化丙啶(PI)双重染色来确定SARS-CoV-2 ORF3a是否可在培养的HEK293T,HepG2和Vero E6细胞中来诱导凋亡。结果发现表达SARS-CoV-2 ORF3a的细胞中膜联蛋白V和PI的染色明显高于对照细胞。此外,基于测量细胞凋亡率的定量数据也证实了ORF3a在不同细胞系中的促凋亡活性。此外,研究人员通过流式细胞术检查了活化的细胞凋亡蛋白酶依赖性细胞凋亡的标志物caspase-3,发现存在ORF3a时,具有激活的caspase-3的细胞百分比显着升高。这些结果表明SARS-CoV-2 ORF3a可以有效诱导细胞凋亡。 为了确定SARS-CoV-2 ORF3a诱导凋亡的机制,研究人员通过蛋白质印迹法检测了表达ORF3a的HEK293T细胞中的凋亡级联反应的激活,并在转染后24小时和48小时探测了一些凋亡途径成分。结果显示SARS-CoV-2 ORF3a可以通过外部途径诱导凋亡,其中活化的caspase-8裂解Bid到tBid,进而诱导线粒体细胞色素c的释放,从而导致凋亡小体形成和caspase-9裂解/激活。 研究人员还研究了膜缔合与SARS-CoV-2 ORF3a促凋亡活性之间的关系,结果表明SARS-CoV-2 ORF3a的促凋亡活性需要膜缔合。研究人员检查了SARS-CoV ORF3a的膜结合和凋亡诱导能力,来研究SARS-CoV-2和SARS-CoV的ORF3a蛋白的促凋亡活性之间是否存在差异。结果表明,与SARS-CoV-2 ORF3a促进凋亡活性涉及膜缔合特征不同,膜缔合对于SARS-CoV ORF3a的促凋亡活性不是必需的,这表明冠状病毒使用不同的策略来诱导凋亡。然后研究人员比较了这两种冠状病毒蛋白之间的促凋亡活性。结果表明,与SARS-CoV-2 ORF3a相比,SARS-CoV ORF3a表达诱导了Vero E6,HEK293T和HepG2细胞中更高的凋亡水平。一致地,在表达SARS-CoV ORF3a的细胞中caspase-3激活水平显着高于表达SARS-CoV-2 ORF3a的细胞。文章表示,这些发现表明,SARS-CoV-2 ORF3a具有比SARS-CoV ORF3a相对弱的促凋亡活性。促凋亡机制和相对强度的差异可能是造成这两种冠状病毒之间致病性差异的原因 文章表示,总而言之,这项工作的发现扩展了对SAF-CoV-2编码的关键辅助蛋白ORF3a的了解,这可能有助于阐明这种致命冠状病毒的致病性。 4.附件: 原文链接:https://www.nature.com/articles/s41423-020-0485-9
  • 《bioRxiv,6月6日,Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-09
    • Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells Shane Miersch, Mart Ustav, Zhijie Li, James B. Case, Safder Ganaie, Giulia Matusali, Francesca Colavita, Daniele Lapa, Maria R. Capobianchi, View ORCID ProfileGuiseppe Novelli, Jang B. Gupta, Suresh Jain, Pier Paolo Pandolfi, Michael S. Diamond, Gaya Amarasinghe, James M. Rini, Sachdev S. Sidhu doi: https://doi.org/10.1101/2020.06.05.137349 Abstract Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds but have crossed the species barrier to infect humans seven times. Of these, three pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and now SARS-CoV-2 coronaviruses, the latter of which is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Here, we describe a panel of synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 spike protein, compete for binding with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar concentrations. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19. Competing Interest Statement S.S, P.P.P and S.J, are cofounders of Virna Therapeutics. The company is developing novel therapies for COVID-19 and other viruses.